|
SHR-1701 Clinical Trials
2 actively recruiting trials
No change since May 2026
Pipeline
Phase 1/2: 1
Top Sponsors
- Nanjing Tianyinshan Hospital1
- Chinese PLA General Hospital1
Indications
- Cancer2
- Liver Disease1
- Relapsed or Refractory Hodgkin Lymphoma1
- Hepatocellular Carcinoma (HCC)1
- Liver Cancer1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.